Public Health, Disease Prevention & Wellness

Tailored Testing Supports Virginia’s Opioid Crisis Response

Tailored Testing Services (TTS) extends its warmest congratulations to Governor Abigail Spanberger on her historic election victory. In partnership with the National Drug & Alcohol Screening Association (NDASA), TTS is committed to supporting the Governor’s administration in addressing substance misuse, opioid addiction, and workforce safety across the Commonwealth.

The Governor’s distinguished background in federal law enforcement uniquely positions her to approach the fight against addiction with clarity, strength, and an understanding of the complex intersections between public safety, public health, and community wellbeing. TTS and NDASA applaud her long-standing dedication to evidence-driven solutions and bipartisan collaboration.

“As NDASA’s Virginia State Affiliate, I am honored to congratulate Governor Spanberger and offer our organization’s full support as she leads Virginia into a new era of responsive, effective action against substance abuse,” said Patrice Waters, President of Tailored Testing Services. “Our expertise in testing, compliance, and workplace safety aligns directly with the priorities facing Virginia today. We look forward to partnering with the administration in any capacity that serves the people of the Commonwealth.”

NDASA and TTS stand ready to assist with strategic insights, workforce-focused initiatives, community engagement, and statewide prevention efforts. Together, the organizations aim to strengthen Virginia’s testing infrastructure, improve access to reliable screening options, and support frontline efforts to combat the challenges associated with opioid use and emerging substances as well as serve as a resource to support employers and communities with education, standards, and practical solutions that promote safer workplaces and healthier communities.

Related posts

Sensus Healthcare Promotes Skin Cancer Awareness with Non-Invasive Treatments

Business Wire

FRIC Completes Enrollment in TRANSFORM II Trial on Coronary Care

PR Newswire

Ethris Doses First Patient in Phase 2a Trial for Asthma Drug

Business Wire